# US 2015/0104868 A1 · Methods of Maintaining and Improving Biological Cell Function and Activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104868 A1
- Document ID: US20150104868A1
- Status: Published application
- Kind: A1
- Application number: 14/396,046
- Filed: 2013-04-19
- Published: 2015-04-16
- Earliest claimed: 2012-04-22
- Assignees: Cargill, Incorporated
- Applicants: Gargill Incorporated
- Inventors: Alvin Berger; Aalt Bast; Petrus Wilhelmus Hubertus De Cock; Gerardus Johannes Martinus Den Hartog; Jean-Claude Marie-Pierre Ghislain De Troostembergh
- Web page: https://patentgrep.com/patent/US20150104868A1

## CPC

- C12N 5/069: {Vascular Endothelial cells}
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A61K 31/047: having two or more hydroxy groups, e.g. sorbitol
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 39/00: General protective or antinoxious agents
- C12N 1/38: Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound (C12N1/34 takes precedence)
- C12N 5/0676: {Pancreatic cells}
- C12N 5/0679: {Cells of the gastro-intestinal tract}
- C12N 2501/999: Small molecules not provided for elsewhere
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to methods of using meso-1,2,3,4-tetrahydroxybutane for the maintenance and/or improvement of biological cell function and activity, and for the prevention of improper cell functioning or cell death, in vitro, ex vivo, and in vivo over time and/or during exposure to stress. Meso-1,2,3,4-tetrahydroxybutane can be used to promote cell survival and as a cell protection agent, to increase cell viability, and to improve conversion of progenitor or stem cells to mature cells, whether in vitro, in vivo, ex-vivo, or transplanted.

## Claims

### Claim 1

Method of maintaining or improving biological function and activity of cells over time and/or during exposure to stress, comprising using meso-1,2,3,4-tetrahydroxybutane, pure or formulated in a product or composition, whereby cells include cells from animals, humans, plants, as well as microorganisms such as bacteria, yeasts and fungi.

### Claim 2

Method of increasing cell viability, comprising using meso-1,2,3,4-tetrahydroxybutane, pure or formulated in a product or composition, as a cell survival and cell protection agent, whereby cells include cells from animals, humans, plants, as well as microorganisms such as bacteria, yeasts and fungi.

### Claim 3

Method of improving conversion of progenitor or stem cells to mature cells, comprising using meso-1,2,3,4-tetrahydroxybutane, pure or formulated in a product or composition, whether in vitro, in vivo, ex-vivo, or transplanted.

### Claim 4 (depends on 1)

The method of claim 1 whereby cells are exposed to stress conditions caused directly or indirectly by glucose or other monosaccharides and disaccharides.

### Claim 5 (depends on 1)

The method of claim 1 where cells are progenitor and mature cells lining up the inside of the vascular system.

### Claim 6 (depends on 1)

The method of claim 1 where cells are progenitor and mature beta cells located in the islets of Langerhans.

### Claim 7 (depends on 1)

The method of claim 1 where cells are progenitor and mature brain cells including but not limited to all cells inside the cranium or in the central spinal canal, in lymphatic tissue, in blood vessels, in the cranial nerves, in the meninges, skull, pituitary gland, or pineal gland.

### Claim 8 (depends on 7)

The method of claim 7 where cells are neurons and glial cells.

### Claim 9 (depends on 8)

The method of claim 8 where cells are astrocytes, oligodendrocytes, and ependymal cells.

### Claim 10 (depends on 1)

The method of claim 1 where cells are microbial intestinal cells as well as progenitor and mature host intestinal cells including but not limited to cells in the colon, rectum, or in the appendix.

### Claim 11 (depends on 1)

The method of claim 1 where cells are progenitor and mature prostate cells.

### Claim 12 (depends on 1)

The method of claim 1 where cells are progenitor and mature breast cells including but not limited to epithelial cells from the ducti and lobules, and adipocytes.

### Claim 13 (depends on 1)

The method of claim 1 where cells are microorganisms used in the fermentation step of the production process of food products chosen from fermented milk or milk derivatives, yogurt, cheese, bread, pastry, sauces, pastes, wine, beer, sauerkraut, kimchi, tempeh, and bean paste, etc.

### Claim 14 (depends on 1)

The method of claim 1 where cells are microorganisms used as production strain for the manufacture of substances that are used as food, food ingredients and additives, nutraceuticals, pharmaceuticals, or personal care products.

### Claim 15 (depends on 2)

The method of claim 2 whereby cells are exposed to stress conditions caused directly or indirectly by glucose or other monosaccharides and disaccharides.

### Claim 16 (depends on 2)

The method of claim 2 where cells are progenitor and mature cells lining up the inside of the vascular system.

### Claim 17 (depends on 2)

The method of claim 2 where cells are progenitor and mature beta cells located in the islets of Langerhans.

### Claim 18 (depends on 3)

The method of claim 3 whereby cells are exposed to stress conditions caused directly or indirectly by glucose or other monosaccharides and disaccharides.

### Claim 19

The method of 3 where cells are progenitor and mature cells lining up the inside of the vascular system.

### Claim 20 (depends on 3)

The method of claim 3 where cells are progenitor and mature beta cells located in the islets of Langerhans.
